Table 2.

Summary of indications, contraindications, and limitations.

	mpMRI	PSMA PET
Indications	Active surveillance
	Loco-regional and distant metastatic disease staging: Primary and Secondary	Loco-regional and distant metastatic disease staging: Primary and Secondary
	Clarification of indeterminant lesions on conventional imaging	Clarification of indeterminant lesions on conventional imaging
	Negative TRUS biopsy and clinical suspicious for undetected prostate cancer	Negative TRUS biopsy and/or mpMRI, and clinical suspicious for undetected prostate cancer
	Assessment of BCR near bladder neck	To determine suitability/treatment response for PSMA targeted theranostic treatment
	Treatment planning—respectability/risk of positive margin
Contra-Indications or Not Recommended for Interpretation	Aneurysm clip
	Embolization coil
	Implanted cardiac device
	Inner ear implant
	Intracranial shunt
	Metal prosthesis
	Neuro/biostimulator
	Ocular metallic foreign body
	Claustrophobia
	Contrast allergy	Contrast allergy
	Unable to lie down	Unable to lie down
Use in Special Circumstances	Contraindicated to prostate biopsy (Coagulopathy, rectal pathology, anterior-perineal resection, immunocompromisation)	Contraindicated to prostate biopsy (Coagulopathy, rectal pathology, anterior-perineal resection, immunocompromisation) Renal impairment
Limitations to Interpretation of Images	Haemorrhage Prostatitis Fibrosis Atrophy Radiotherapy Hormonal therapy Renal impairment Prosthesis	Local recurrence near bladder neck or a metastatic deposit near bladder. Non-PSMA producing tumour including aggressive tumours such as small cell, neuroendocrine and ductal carcinoma types. Physiological expression in lacrimal or salivary glands, liver, spleen, kidneys, small bowel and ganglia. Benign and malignant tumours with neovascularisation.